Status:
RECRUITING
Decoding the Inflammasome Influence on Treatment Response in Acute Myeloid Leukemia
Lead Sponsor:
Ciceri Fabio
Collaborating Sponsors:
Azienda Ospedaliera Bianchi-Melacrino-Morelli
Conditions:
Acute Myeloid Leukemia
Eligibility:
All Genders
18+ years
Brief Summary
The study is designed as a collection of biological samples of newly diagnosed acute myeloid leukemia (AML) patients treated in the clinical units involved. Samples of peripheral blood (PB) and bone m...
Detailed Description
Acute myeloid leukemia (AML) is a highly aggressive and unfavorable malignancy primarily affecting bone marrow (BM) myeloid cells, particularly in older individuals. The standard treatment for fit, in...
Eligibility Criteria
Inclusion
- Any gender,
- Adults (\>18 years old),
- New suspect diagnosis of acute myeloid leukemia (ELN2022 Criteria)
- Capable of comprehend the study and the consent form,
- Willing to sign the informed consent for the study.
- For the retrospective population we will select:
- biological samples (BM Biopsies, BM Aspirates and PB) already banked upon research purpose informed consent and collected from the 01/06/2006 up to 01/06/2024 from adults patients with diagnosis of acute myeloid leukemia according to ELN2017 Criteria.
Exclusion
- Pediatric patients (\<18 years old),
- Patients unable or unwilling to sign the informed consent.
Key Trial Info
Start Date :
February 22 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 31 2026
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT06535113
Start Date
February 22 2025
End Date
August 31 2026
Last Update
May 8 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
GOM Bianchi Melacrino Morelli
Reggio Calabria, Calabria, Italy, 89133
2
IRCCS Ospedale San Raffaele
Milan, Milan, Italy, 20132